Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib activity in schwannomas
ISRCTN49989464Phase 4Completed
- Sponsor
- University Hospitals Plymouth
- Start
- Feb 2012
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of sorafenib in schwannoma and neurofibromatosis type 2 (NF2), sponsored by University Hospitals Plymouth. Primary endpoint: Target inhibition by sorafenib in cutaneous schwannoma biopsies. Started Feb 2012; status: completed.
02
Drugs
sorafenib
03
Conditions
schwannomaneurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on ISRCTN49989464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49989464.